市場調查報告書
商品編碼
1521301
2024-2032 年按產品類型(分析儀、消耗品)、模式(台式、攜帶式)、最終用戶(醫院、診所、門診手術中心等)和地區分類的血氣和電解質分析儀市場報告Blood Gas and Electrolyte Analyzer Market Report by Product Type (Analyzers, Consumables), Modality (Benchtop, Portable), End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Region 2024-2032 |
IMARC Group年,全球血氣及電解質分析儀市場規模達21億美元。
血氣和電解質分析儀是指用於測量全血樣本中各種參數的醫療設備,包括血氣(二氧化碳和氧氣的分壓)、pH、電解質和代謝物。它們廣泛用於檢測代謝失衡以及測量腎臟和心臟功能。它們還有助於確定血液中異常的電解質水平、氧氣或二氧化碳交換水平以及患者的酸鹼平衡。此外,它們還有助於識別糖尿病、血管出血和藥物消耗。近年來,血液氣體和電解質分析儀因其易用性、成本效益、準確性和快速結果而在臨床診斷實驗室和重症監護病房中廣受歡迎。
血液氣體和電解質分析儀可以簡化工作流程,最大限度地減少錯誤,需要最少的維護,並快速提供準確的結果。因此,重症監護病房(ICU)、手術室和急診科的患者數量不斷增加是推動市場成長的主要因素。除此之外,糖尿病和心血管疾病等慢性疾病的廣泛流行,以及更容易患這些疾病的老年人口的不斷增加,都增加了產品需求。此外,對高吞吐量、整合和自動化系統的需求也顯著增加。同時,血氣和電解質分析儀與實驗室資訊系統和電子病歷的不斷整合,以簡化工作流程並能夠有效監測患者健康狀況,正在促進市場成長。此外,一些領先的參與者正在大力投資開發攜帶式血氣和電解質分析儀,這些分析儀具有易於使用和操作的特性以及最低的維護要求。其他因素,包括對即時檢測 (POCT) 偏好的轉變、醫療保健行業的發展、技術進步、產品創新以及廣泛的研發 (R&D) 活動,也正在創造有利的市場前景。
The global blood gas and electrolyte analyzer market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.
Blood gas and electrolyte analyzers refer to medical devices used to measure various parameters, including blood gas (partial pressure of carbon dioxide and oxygen), pH, electrolytes, and metabolites, in a whole blood sample. They are widely utilized for the detection of metabolic imbalances and the measurement of renal and cardiac functions. They also help determine abnormal electrolyte levels in the blood, levels of oxygen or carbon dioxide exchange, and the acid-base balance of the patient. Moreover, they assist in identifying diabetes, blood vessel hemorrhage, and drug consumption. In recent years, blood gas and electrolyte analyzers have gained immense popularity across clinical diagnostic labs and critical care units due to their ease of use, cost-effectiveness, accuracy, and fast results.
Blood gas and electrolyte analyzers can streamline work processes, minimize errors, require minimum maintenance, and provide accurate results quickly. As a result, the increasing number of patients in intensive care units (ICUs), operating rooms, and emergency departments represent the primary factor driving the market growth. Besides this, the widespread prevalence of chronic diseases, such as diabetes and cardiovascular disorders, and the growing geriatric population that is more susceptible to developing these medical ailments are augmenting the product demand. Additionally, there has been a significant increase in the demand for high throughput, integrated, and automated systems. Along with this, the rising integration of blood gas and electrolyte analyzers with laboratory information systems and electronic medical records to streamline the workflow and enable effective monitoring of patient health is catalyzing the market growth. Furthermore, several leading players are making heavy investments for the development of portable blood gas and electrolyte analyzers with easy-to-use and handle features and minimum maintenance requirements. Other factors, including the shifting preferences toward point-of-care testing (POCT), developments in the healthcare industry, technological advancements, product innovations, and extensive research and development (R&D) activities, are also creating a favorable market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global blood gas and electrolyte analyzer market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, modality and end user.
Analyzers
Consumables
Benchtop
Portable
Hospitals
Clinics
Ambulatory Surgical Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories Inc., Dalko Diagnostics, Erba Group (Transasia Bio-Medicals Ltd.), Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems Inc. (IDEXX Laboratories), Radiometer Medical ApS (Danaher Corporation), Roche Holding AG, Siemens AG, and WerfenLife S.A.